BioCentury
ARTICLE | Clinical News

Tarloxotinib Bromide: Phase II started

August 17, 2015 7:00 AM UTC

Threshold began an open-label, U.S. and Australian Phase II trial to evaluate 150 mg/m 2 IV TH-400 on days 1, 8, 15 and 22 of a 28-day cycle in up to 37 patients with stage IV, EGFR-positive, T790M-ne...